Search Results - "Moebus, V"

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials by Coleman, R, Powles, T, Paterson, A, Gnant, M, Anderson, S, Diel, I, Gralow, J, von Minckwitz, G, Moebus, V, Bergh, J, Pritchard, KI, Bliss, J, Cameron, D, Evans, V, Pan, H, Peto, R, Bradley, R, Gray, R, Bartsch, R, Dubsky, P, Fesl, C, Fohler, H, Greil, R, Jakesz, R, Lang, A, Luschin-Ebengreuth, G, Marth, C, Mlineritsch, B, Samonigg, H, Singer, CF, Steger, GG, Stoger, H, Olivotto, I, Ragaz, J, Christiansen, P, Ejlertsen, B, Ewertz, M, Jensen, MB, Moller, S, Mouridsen, HT, Eiermann, W, Hilfrich, J, Jonat, W, Kaufmann, M, Kreienberg, R, Schumacher, M, Blohmer, JU, Costa, SD, Eidtmann, H, Gerber, B, Jackisch, C, Loibl, S, Dafni, U, Markopoulos, C, Blomqvist, C, Saarto, T, Ahn, JH, Jung, KH, Perrone, F, Bass, G, Brown, A, Bryant, J, Costantino, J, Dignam, J, Fisher, B, Geyer, C, Mamounas, EP, Paik, S, Redmond, C, Swain, S, Wickerham, L, Wolmark, N, Perez, E, Ingle, JN, Suman, VJ, Hadji, P, A'Hern, R, Dowsett, M, Makris, A, Parton, M, Pennert, K, Powles, TJ, Smith, IE, Yarnold, JR, Clack, G, Van Poznak, C, Safra, T, Bell, R, Coleman, RE, Dodwell, D, Hinsley, S, Marshall, HC, Solomayer, E, Fehm, T, Lester, J, Winter, MC, Horsman, JM, Aft, R, Brufsky, AM, Llombart, HA

“…Summary Background Bisphosphonates have profound effects on bone physiology, and could modify the process of metastasis. We undertook collaborative…”
Get full text

Reply to the letter to the editor ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by Daly et al by Furlanetto, J., Loibl, S., Moebus, V.

Get full text

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients by Matikas, A., Foukakis, T., Moebus, V., Greil, R., Bengtsson, N. -O., Steger, G.G., Untch, M., Johansson, H., Hellström, M., Malmström, P., Gnant, M., Loibl, S., Bergh, J.

“…Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could…”
Get full text

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis by Aapro, M., Moebus, V., Nitz, U., O'Shaughnessy, J., Pronzato, P., Untch, M., Tomita, D., Bohac, C., Leyland-Jones, B.

“…A meta-analysis of trials of ESA use in patients with breast cancer receiving chemotherapy was conducted. Nine studies were analyzed (ESAn = 2346; controln =…”
Get full text

Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy by Papakonstantinou, A., Matikas, A., Hellström, M., Johansson, H., Steger, G., Greil, R., Loibl, S., Gnant, M., Moebus, V., Untch, M., Foukakis, T., Bergh, J.

Get full text

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study by Mavratzas, A., Baek, S., Gerber, B., Schmidt, M., Moebus, V., Foerster, F., Grischke, E.M., Fasching, P., Strumberg, D., Solomayer, E., Klare, P., Windemuth-Kieselbach, C., Hartmann, S., Schneeweiss, A., Marmé, F.

“…This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor…”
Get full text

Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study by Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P.A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Müller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R.K., Hahnen, E., Loibl, S.

Get full text

Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients by Reinisch, M., Seiler, S., Hauzenberger, T., Schmatloch, S., Strittmatter, H.-J., Zahm, D.-M., Thode, C., Jackisch, C., Strik, D., Moebus, V., Reimer, T., Sinn, B., Stickeler, E., Marme, F., Janni, W., Kamischke, A., Rudlowski, C., Nekljudova, V., von Minckwitz, G., Loibl, S.

Get full text

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga by Aapro, M., Moebus, V., Nitz, U., O'Shaughnessy, J., Pronzato, P., Untch, M., Tomita, D., Bohac, C., Leyland-Jones, B.

Get full text

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up by Zander, A.R., Schmoor, C., Kröger, N., Krüger, W., Möbus, V., Frickhofen, N., Metzner, B., Berdel, W.E., Koenigsmann, M., Thiel, E., Wandt, H., Possinger, K., Kreienberg, R., Schumacher, M., Jonat, W.

“…Investigation of high-dose chemotherapy (HD-CT) compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer…”
Get full text

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group by du Bois, A., Lück, H. J., Pfisterer, J., Schroeder, W., Blohmer, J. U., Kimmig, R., Moebus, V., Quaas, J.

“…Background: Despite the progress that has been achieved in the last years, recurrence rates in ovarian cancer patients are still considerably high and the…”
Get full text

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer by DU BOIS, A, MEIER, W, RICHTER, B, WAGNER, U, LÜCK, H. J, EMONS, G, MOEBUS, V, SCHROEDER, W, COSTA, S, BAUKNECHT, T, OLBRICHT, S, JACKISCH, C

“…The majority of patients with ovarian cancer are not cured by first-line treatment. Until now, no study could demonstrate any substantial benefit when exposing…”
Get full text

Epidermal Growth Factor Receptor (EGFR) Mutation Does Not Correlate with Platinum Resistance in Ovarian Carcinoma. Results of a Prospective Pilot Study by MUSTEA, Alexander, SEHOULI, Jalid, FABJANI, Gerhild, KOENSGEN, Dominique, MÖBUS, V, BRAICU, Elena Ioana, PIRVULESCU, Cristina, THOMAS, Anke, DAN TONG, ZEILLINGER, Robert

“…Background: Different studies have demonstrated epidermal growth factor receptor (EGFR) status as an independent prognostic factor for ovarian cancer (OC)…”
Get full text

Phase I II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer by FRICKHOFEN, N, BERDEL, W. E, KREIENBERG, R, HINKE, A, MÖBUS, V, OPRI, F, HAAS, R, SCHNEEWEISS, A, SANDHERR, M, KUHN, W, HOSSFELD, D. K, THOMSSEN, C, HEIMPEL, H

“…Ovarian cancer is chemosensitive, but most patients with advanced disease die from tumor progression. As 25% of the patients can be cured by chemotherapy, it…”
Get full text

An interdisciplinary approach to postpartum depression by Oddo, S, Thiel, A, Klinger, D, Wuerzburg, J, Steetskamp, J, Oezkartal, T, Stober, K, Moebus, V, Grube, M, Louwen, F, Stirn, A, Grabmair, C

Get full text

Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives by Moebus, V J, Stein, R, Kieback, D G, Runnebaum, I B, Sass, G, Kreienberg, R

“…Cisplatin, Carboplatin and new compounds such as Paclitaxel and Docetaxel are effective drugs in the treatment of ovarian cancer. Multidrug resistance however…”
Get more information

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry by Witzel, I., Laakmann, E., Weide, R., Neunhöffer, T., Park-Simon, T.-J., Schmidt, M., Fasching, P.A., Hesse, T., Polasik, A., Mohrmann, S., Würschmidt, F., Schem, C., Bechtner, C., Würstlein, R., Fehm, T., Möbus, V., Burchardi, N., Loibl, S., Müller, V.

“…Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and…”
Get full text

258P - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy by Papakonstantinou, A., Matikas, A., Hellström, M., Johansson, H., Steger, G., Greil, R., Loibl, S., Gnant, M., Moebus, V., Untch, M., Foukakis, T., Bergh, J.

“…Adjuvant dose-dense chemotherapy improves breast cancer (BC) outcomes compared to standard chemotherapy, with no increase in chemotherapy-induced amenorrhea…”
Get full text

258PImpact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy by Papakonstantinou, A, Matikas, A, Hellström, M, Johansson, H, Steger, G, Greil, R, Loibl, S, Gnant, M, Moebus, V, Untch, M, Foukakis, T, Bergh, J

“…Abstract Background Adjuvant dose-dense chemotherapy improves breast cancer (BC) outcomes compared to standard chemotherapy, with no increase in…”
Get full text

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial by Papakonstantinou, Antroula, Matikas, Alexios, Bengtsson, Nils Olof, Malmström, Per, Hedayati, Elham, Steger, Guenther, Untch, Michael, Hübbert, Laila, Johansson, Hemming, Hellström, Mats, Gnant, Michael, Loibl, Sibylle, Greil, Richard, Moebus, Volker, Foukakis, Theodoros, Bergh, Jonas

“…Background Dose‐dense (DD) adjuvant chemotherapy improves outcomes in early breast cancer (BC). However, there are no phase 3 randomized data to inform on its…”
Get full text